CONMED Yönetim

Yönetim kriter kontrolleri 3/4

CONMED CEO'su Curt Hartman, Jul2014 tarihinde atandı, in görev süresi 10.33 yıldır. in toplam yıllık tazminatı $ 7.76M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.2% maaş ve 87.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.3% ine doğrudan sahiptir ve bu hisseler € 6.32M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 9.3 yıldır.

Anahtar bilgiler

Curt Hartman

İcra Kurulu Başkanı

US$7.8m

Toplam tazminat

CEO maaş yüzdesi	12.2%
CEO görev süresi	10.3yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	9.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Curt Hartman'un ücretlendirmesi CONMED'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$132m
Jun 30 2024	n/a	n/a	US$99m
Mar 31 2024	n/a	n/a	US$82m
Dec 31 2023	US$8m	US$950k	US$64m
Sep 30 2023	n/a	n/a	US$58m
Jun 30 2023	n/a	n/a	US$88m
Mar 31 2023	n/a	n/a	-US$94m
Dec 31 2022	US$8m	US$946k	-US$81m
Sep 30 2022	n/a	n/a	-US$83m
Jun 30 2022	n/a	n/a	-US$114m
Mar 31 2022	n/a	n/a	US$68m
Dec 31 2021	US$9m	US$918k	US$63m
Sep 30 2021	n/a	n/a	US$62m
Jun 30 2021	n/a	n/a	US$54m
Mar 31 2021	n/a	n/a	US$13m
Dec 31 2020	US$6m	US$888k	US$10m
Sep 30 2020	n/a	n/a	US$311k
Jun 30 2020	n/a	n/a	US$431k
Mar 31 2020	n/a	n/a	US$34m
Dec 31 2019	US$6m	US$842k	US$29m
Sep 30 2019	n/a	n/a	US$29m
Jun 30 2019	n/a	n/a	US$28m
Mar 31 2019	n/a	n/a	US$31m
Dec 31 2018	US$5m	US$791k	US$41m
Sep 30 2018	n/a	n/a	US$72m
Jun 30 2018	n/a	n/a	US$73m
Mar 31 2018	n/a	n/a	US$71m
Dec 31 2017	US$3m	US$753k	US$55m

Tazminat ve Piyasa: Curt 'nin toplam tazminatı ($USD 7.76M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.61M ).

Tazminat ve Kazançlar: Curt 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Curt Hartman (60 yo)

10.3yrs

Görev süresi

US$7,764,615

Tazminat

Mr. Curt R. Hartman serves as the Director of CONMED Corporation since October 31, 2024 and Chief Executive Officer and President of CONMED Corporation since November 09, 2014, He served as Chairman of the...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Curt Hartman	President	10.3yrs	US$7.76m	0.30% € 6.3m
Todd Garner	Executive VP	6.8yrs	US$2.87m	0.00073% € 15.2k
Patrick Beyer	Chief Operating Officer	less than a year	US$3.30m	0.035% € 730.7k
Richard Glaze	Chief Information Officer	no data	Veri yok	Veri yok
Hollie Foust	General Counsel & Corporate Secretary	no data	Veri yok	Veri yok
Peter Shagory	Executive Vice President of Strategy & Corporate Development	9.5yrs	Veri yok	0.012% € 250.9k
Shanna Cotti-Osmanski	Executive VP of Information Technology & CIO	4.7yrs	Veri yok	Veri yok
John Ferrell	Executive Vice President of Human Resources	1.9yrs	Veri yok	0.0023% € 47.4k
David Murray	President of ConMed Electrosurgery	20.3yrs	US$572.33k	Veri yok
Johonna Pelletier	VP of Tax & Treasurer	9.6yrs	Veri yok	0.0043% € 89.0k
Kimberly Lockwood	Interim Corporate Controller	less than a year	Veri yok	Veri yok

5.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: EC8 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Curt Hartman	President	10.7yrs	US$7.76m	0.30% € 6.3m
John Workman	Independent Director	9.3yrs	US$257.37k	0.066% € 1.4m
David Bronson	Independent Director	9.3yrs	US$264.87k	0.054% € 1.1m
Brian Concannon	Independent Director	11.3yrs	US$257.37k	0.031% € 651.8k
LaVerne Council	Independent Director	4.9yrs	US$257.37k	0.012% € 241.3k
Martha Aronson	Independent Chair of the Board	8.8yrs	US$292.37k	0.045% € 940.9k
Charles Farkas	Independent Director	10.3yrs	US$249.87k	0.066% € 1.4m
Barbara Schwarzentraub	Independent Director	5.2yrs	US$264.87k	0.017% € 358.9k

9.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: EC8 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.3 yıldır).

CONMED Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

Insider recently sold €151k worth of stock

Chairman of the Board recently sold €433k worth of stock

Recent updates

Investor sentiment improves as stock rises 17%

New minor risk - Earnings quality

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings released: EPS: US$1.59 (vs US$0.52 in 3Q 2023)

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation Announces Chief Executive Officer Changes

CONMED Corporation to Report Q3, 2024 Results on Oct 30, 2024

Upcoming dividend of US$0.20 per share

Second quarter dividend of US$0.20 announced

CONMED Corporation Announces Termination of Stanley W. (Bill) Peters as President, Advanced Surgical & Advanced Endoscopic Technologies, Effective August 31, 2024

Second quarter 2024 earnings released: EPS: US$0.97 (vs US$0.45 in 2Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation to Report Q2, 2024 Results on Jul 31, 2024

Upcoming dividend of US$0.20 per share

First quarter dividend of US$0.20 announced

CONMED Corporation Declares Quarterly Cash Dividend, Payable on July 5, 2024

First quarter 2024 earnings released: EPS: US$0.64 (vs US$0.06 in 1Q 2023)

CONMED Corporation Revises Earnings Guidance for the Full Year 2024

CONMED Corporation, Annual General Meeting, May 22, 2024

CONMED Corporation to Report Q1, 2024 Results on Apr 24, 2024

Upcoming dividend of US$0.20 per share

Fourth quarter dividend of US$0.20 announced

Full year 2023 earnings released: EPS: US$2.10 (vs US$2.68 loss in FY 2022)

CONMED Corporation Declares Quarterly Cash Dividend, Payable on April 5, 2024

Full year 2023 earnings released: EPS: US$2.10 (vs US$2.68 loss in FY 2022)

CONMED Corporation Provides Financial Guidance for the Full Year 2024

Investor sentiment deteriorates as stock falls 16%

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2024

Third quarter 2023 earnings released: EPS: US$0.52 (vs US$1.51 in 3Q 2022)

CONMED Corporation Updates Third Quarter Guidance for 2023

CONMED Corporation to Report Q3, 2023 Results on Oct 25, 2023

Upcoming dividend of US$0.20 per share at 0.7% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$5.65 loss in 2Q 2022)

CONMED Corporation Revises Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q2, 2023 Results on Jul 26, 2023

Upcoming dividend of US$0.20 per share at 0.6% yield

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2023

Insider recently sold €151k worth of stock

First quarter 2023 earnings released: EPS: US$0.06 (vs US$0.51 in 1Q 2022)

Chairman of the Board recently sold €433k worth of stock

Upcoming dividend of US$0.20 per share at 0.8% yield

Full year 2022 earnings released: US$2.68 loss per share (vs US$2.15 profit in FY 2021)

CONMED Corporation Provides Earnings Guidance for the Full Year 2023

CONMED Corporation to Report Q4, 2022 Results on Feb 02, 2023

Now 21% undervalued after recent price drop

CONMED Corporation Announces Management Changes

CONMED Corporation Announces Quarterly Cash Dividend, Payable on January 5, 2023

Insufficient new directors

CONMED Corporation Provides Revenue Guidance for the Full Year 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$1.51 (vs US$0.51 in 3Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q3, 2022 Results on Oct 26, 2022

Insufficient new directors

Chairman of the Board recently sold €329k worth of stock

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on October 5, 2022

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) completed the acquisition of Biorez, Inc.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

CONMED Corporation (NYSE:CNMD) has entered into a definitive agreement to acquire Biorez, Inc. for $250 million.

Second quarter 2022 earnings released: US$5.65 loss per share (vs US$0.46 profit in 2Q 2021)

CONMED Corporation Revises Earnings Guidance for the Full Year 2022

CONMED Corporation to Report Q2, 2022 Results on Jul 27, 2022

CONMED Corporation(NYSE:CNMD) dropped from Russell 2000 Dynamic Index

CONMED Corporation (NYSE:CNMD) completed the acquisition of In2Bones Global, Inc.

Upcoming dividend of US$0.20 per share

CONMED Corporation Announces Quarterly Cash Dividend, Payable on July 5, 2022